文献速递呼吸道感染呼吸危重症与机械通气

抗GM-CSF抗体otilimab治疗重症COVID-19肺炎的随机试验(OSCAR)

A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
PubMed 文献 · Eur Respir J · 2023-02-02

OSCAR研究是一项随机、序贯、多中心、安慰剂对照、双盲试验,纳入重症COVID-19伴呼吸衰竭和全身炎症的成人患者,评估单次静脉输注otilimab 90 mg联合标准治疗的效果。主要结局第28天存活且无呼吸衰竭的比例在otilimab组为71%、安慰剂组为67%,模型校正差异5.3%无统计学显著性(95%CI -0.8-11.4%,p=0.09)。尽管无临床获益,otilimab降低了关键炎症标志物水平,安全性可接受。

要点

  • otilimab 90 mg单次静脉输注未显著提高第28天存活且无呼吸衰竭比例(71% vs 67%,p=0.09)。
  • 预设70-79岁亚组显示名义显著差异19.1%,但第二部分未确认(差异0.9%,p=0.86)。
  • otilimab降低血清炎症标志物(包括CCL17),提示GM-CSF通路阻断,安全性可接受。

核心结论

  • otilimab治疗重症COVID-19肺炎在第28天存活且无呼吸衰竭比例上未显示显著差异。
  • 尽管无临床获益,otilimab降低了炎症标志物水平且安全性可接受。

研究设计与样本

  • 随机、序贯、多中心、安慰剂对照、双盲研究(NCT04376684)。
  • 第一部分纳入18-79岁患者806例按1:1随机接受otilimab 90 mg或安慰剂。
  • 第二部分纳入≥70岁患者350例随机。
  • 干预为单次静脉输注otilimab 90 mg联合标准治疗。

主要发现

  • 第一部分第28天存活且无呼吸衰竭比例:otilimab组71%,安慰剂组67%,模型校正差异5.3%(95%CI -0.8-11.4%,p=0.09)。
  • 预设70-79岁亚组模型校正差异19.1%(95%CI 5.2-33.1%,p=0.009),但第二部分未确认(差异0.9%,95%CI -9.3-11.2%,p=0.86)。
  • otilimab降低血清关键炎症标志物浓度,包括CC趋化因子配体17。
  • 不良事件两组相当,与重症COVID-19一致。

关键数值与推荐

  • 主要结局为第28天存活且无呼吸衰竭的比例。
  • 第一部分otilimab组71% vs 安慰剂组67%,差异5.3%(95%CI -0.8-11.4%,p=0.09)。
  • 70-79岁亚组差异19.1%(95%CI 5.2-33.1%,p=0.009)。
  • 第二部分差异0.9%(95%CI -9.3-11.2%,p=0.86)。

临床怎么用

  • 不推荐对重症COVID-19肺炎患者常规使用otilimab 90 mg单次静脉输注以改善第28天无呼吸衰竭生存。
  • otilimab可降低炎症标志物,但未转化为临床获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Granulocyte-macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology and severity of COVID-19. METHODS: In this randomised, sequential, multicentre, placebo-controlled, double-blind study, adults aged 18-79 years (Part 1) or ≥70 years (Part 2) with severe COVID-19, respiratory failure and systemic inflammation (elevated C-reactive protein/ferritin) received a single intravenous infusion of otilimab 90 mg (human anti-GM-CSF monoclonal antibody) plus standard care (NCT04376684). The primary outcome was the proportion of patients alive and free of respiratory failure at Day 28. RESULTS: In Part 1 (n=806 randomised 1:1 otilimab:placebo), 71% of otilimab-treated patients were alive and free of respiratory failure at Day 28 versus 67% who received placebo; the model-adjusted difference of 5.3% was not statistically significant (95% CI -0.8-11.4%, p=0.09). A nominally significant model-adjusted difference of 19.1% (95% CI 5.2-33.1%, p=0.009) was observed in the predefined 70-79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI -9.3-11.2%, p=0.86). Compared with placebo, otilimab resulted in lower serum concentrations of key inflammatory markers, including the putative pharmacodynamic biomarker CC chemokine ligand 17, indicative of GM-CSF pathway blockade. Adverse events were comparable between groups and consistent with severe COVID-19. CONCLUSIONS: There was no significant difference in the proportion of patients alive and free of respiratory failure at Day 28. However, despite the lack of clinical benefit, a reduction in inflammatory markers was observed with otilimab, in addition to an acceptable safety profile.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Patel J, Bass D, Beishuizen A, et al. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). Eur Respir J. 2023. PMID: 36229048. doi:10.1183/13993003.01870-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。